146 results about "Binding inhibition" patented technology

Provided is a method of treating a proliferative disease, condition, or disorder in a subject by administering a combination of an inhibitor of p53 and MDM2 binding and an EGFR inhibitor. Various embodiments of the disclosed methods provide a synergistic anti-proliferative or anti-apoptotic effect compared to administration of one agent alone.

The present invention relates to a method of identifying an inhibitor of a receptor tyrosine kinase that irreversibly binds to the kinase. Specifically, the method comprises using a variety of assays, either alone or in combination, to identify compounds that irreversibly bind to tyrosine kinases. More specifically, there are four assays, which are novel variations of a basic enzyme assay and identify irreversible binding inhibitors.

The present invention relates to a group of new oligonucleotides sequences with human tumor necrosis factor α (TNF-α) inhibiting activity, which includes DNA sequences and RNA sequences. These oligonucleotides or aptamer can specifically be bound to TNF-α and inhibit the cytoxicity of TNF-α to L929 cells. Therefore, the aptamer of the present invention may be used to detect TNF-α and provide a therapeutic method for diseases related to the increasing level of TNF-α. Compared with other TNF antagonists such as monoclonal antibody and soluble receptor, the present invention has high specificity, high affinity, quick penetration to target tissue, rapid plasma clearance, and lower immunogenecity. Turthermore, it can be used repeatedly and keeps high concentration in target tissue and the like. It has the advantages of affinity and specificity similar to monoclonal antibodies and also has permeability and pharmacokinetics characteristics similar to small molecular polypeptide. The present invention also refers to derivative of the oligonucleotides sequence, including modified sequence. The present invention may further be manufactured as medicine for therapy and diagnosis of TNF-α related diseases.

The present invention relates to the field of disease treatment and immunology, and in particular, to anti-TIGIT antibodies or antigen-binding fragments thereof, nucleic acid molecules encoding the anti-TIGIT antibody and the antigen-binding fragment, and a preparation method thereof. The anti-TIGIT antibody or the antigen binding fragment thereof provided by the invention has high specificity andhigh affinity to TIGIT, can effectively block the binding of TIGIT and a ligand thereof, and inhibits and/or blocks intracellular signal transduction mediated by the binding of TIGIT and the ligand thereof. Therefore, the invention further relates to a pharmaceutical composition comprising said antibody or antigen-binding fragment thereof, and to the use thereof in the preparation of a medicine for enhancing immune cell activity, enhancing immune response, or for preventing and/or treating tumors, infections or infectious diseases.

The invention provides a method of detecting surrogate markers for active tuberculosis in a serum sample. The surrogate markers are selected from serum mycolic acid antigen, serum anti-mycolic acid antibodies or both. The method includes the steps of combining the serum sample with a labelled monoclonal immunoglobulin antibody or fragment thereof to mycolic acids to produce a combined serum sample, the antibody or fragment thereof not substantially cross-reacting with cholesterol and the label being selected so that binding of the labelled antibody to immobilized mycolic acid antigen of mycobacterial origin produces a detectable signal and combining a blank sample with the labelled monoclonal immunoglobulin antibody or fragment thereof to mycolic acid to produce a combined blank sample. The method includes exposing both samples to immobilised mycolic acid antigen of mycobacterial origin or a synthetic analogue or analogues thereof so that the labelled immunoglobulin antibodies or fragments thereof in each sample bind to the immobilised antigen to produce detectable signals. If the surrogate markers are present, the signal produced by the blank sample will be stronger than that produced by the serum sample because of inhibition of binding of the labelled antibody in the serum sample arising from prior binding of the labelled antibody with the mycolic acid antigen in the serum sample or by competitive binding of serum anti-mycolic acid antibodies in the serum sample to the immobilised mycolic acid antigen or both.

A method of inhibiting complement activation mediated by C3b inhibitors in a subject is provided. The method includes administering a C3b inhibitor to the subject to inhibit at least one of C3b binding to factors B and properdin, to inhibit C3 cleavage, to inhibit the activation of neutrophils, monocytes, platelets, and endothelium; or to inhibit the formation of C3a, C5a, and MAC.

The invention relates to the field of biological medicine, and discloses a fully human monoclonal neutralizing antibody for resisting novel coronavirus and application of the fully human monoclonal neutralizing antibody. B-type lymphocytes are screened from blood of a new coronal pneumonia rehabilitation patient, and the affinity constant of the obtained antibody and a virus receptor binding domain (RBD) is 1.19 nM. X-ray crystal diffraction is used for analyzing the three-dimensional structure of the antibody and RBD compound, it is found that the binding epitope of the antibody and the binding epitope of a host cell receptor (ACE2) are highly overlapped, binding of the RBD and the ACE2 can be competitively blocked, and infection of the RBD and the ACE2 is inhibited. The antibody can cope with certain genetic mutations of viruses, the half effective concentration of the antibody for blocking pseudoviruses (accumulated B.1. 1.7 mutant strain genes and D614G) from infecting host cells is 0.57 ng/mL, and the antibody has the advantages of safety, high efficiency and broad spectrum, and is expected to be used as a neutralizing antibody drug for diagnosing, treating and preventing new coronal pneumonia.

The invention discloses a method for detecting residual kanamycin and application thereof, and belongs to the technical field of analysis chemistry, wherein the detection method is based on aptamer initiated cyclic enzyme digestion of exonuclease III (Exo III). According the method, mercapto self-assembly is utilized, single stranded DNA (ssDNA) that is complementary with kanamycin aptamer (K-aptamer) is grafted on the surface of a gold electrode, then a little amount of K-aptamer is added, and the K-aptamer is matched with ssDNA to form a little amount of double stranded DNA (dsDNA). Then Exo III is added, the ssDNA in dsDNA can be specifically digested by Exo III, thus the residual aptamers are released, the released aptamers can combine with ssDNA to form dsDNA, another enzyme digestion is triggered then, and after several circulations, the modified ssDNA is completely digested by enzymes. Kanamycin exists in the system, through the combination between kanamycin and aptamers, the circulation enzyme digestion is inhibited, thus ssDNA is preserved, and the amount of preserved ssDNA is related with the concentration of kanamycin. An electro-analysis method is used to absorb electrical signal molecules namely hexaammine ruthenium (RuHeX) through static electricity absorption so as to quantitatively detect residual kanamycin; and the method has high sensitivity and can sensitively detect residual kanamycin in milk.

The invention provides a hydroquinone farnesyl group compound and application of a pharmaceutical salt thereof in serving as an alpha-glucosidase, protein-tyrosine-phosphatase 1B or HMG-CoA reductase inhibitor, or in preparing drug for treating and/or preventing type-II diabetes or hyperlipidemia, or in preparing drug or functional healthcare products having hypoglycemic and hypolipidemic functions, or in preparing drug or functional healthcare products having a function of treating or preventing non-alcoholic fatty liver disease, or in preparing drug or functional healthcare products having liver protection effect, or in preparing drug or functional healthcare products for preventing and/or treating cancer or inhibiting tumor cell proliferation, or in serving as an RXRalpha receptor binding inhibitor, or in preparing drug serving as the RXRalpha receptor binding inhibitor. The inhibitors, the drug, food or the healthcare products prepared through the hydroquinone farnesyl group compound and the pharmaceutical salt are free of toxic and side effect and remarkable in treatment effect.

The invention provides an anti-human IL-33 monoclonal antibody and application thereof. By taking recombinant human IL-33 as an immunogen, a murine anti-human IL-33 monoclonal antibody is prepared through a hybridoma technique; binding activity analysis is carried out on the murine antibody, blocking activity analysis is carried out on binding of IL-33 and ST2, sequencing is carried out, a human-mouse chimeric anti-human IL-33 monoclonal antibody is constructed, and kinetic parameters of the chimeric antibody are detected. On the basis of performance analysis of the murine antibody and the chimeric antibody, a humanized anti-human IL-33 monoclonal antibody is constructed by adopting a CDRs transplantation technology and a complementary determining region (CDR) mutation design, kinetic parameters and affinity of the humanized antibody are detected, and IL33-induced cytokine release is blocked. The anti-human IL-33 monoclonal antibody has relatively high affinity to IL-33, can effectively block binding of IL-33 and a receptor ST2 thereof, inhibits immune response related to an IL-33/ST2 pathway, and has a good application prospect in treatment of asthma, inflammatory diseases, diabetes and autoimmune diseases.

This invention provides improved polyamides comprising a hairpin loop derived from γ-aminobutyric acid which bind to the minor groove of a promoter regions of a DNA sequence. Binding of the polyamide to the DNA sequence of the promoter region inhibits expression of the requisite gene. The improvement relates to the use of R-2,4-diaminobutyric acid and derivatives of the 2-amino group to form the hairpin loop. The improved asymmetric hairpin provides for tighter binding of the polyamides to the minor groove of DNA and additionally provides an amine function for derivatizing polyamides by, for example, forming amide linkages. Such derivatives may serve to attach detectable labels to the polyamide.

A method for treating inflammatory joint diseases by inhibiting cadherin-11 mediated cellular function using a cadherin-11 modulating agent is provided. Also provided are screening assays for identifying pharmaceutical lead compounds capable of modulating cellular functions of cadherin-11 such as cell proliferation, apoptosis, factor secretion, and binding of cadherin-11 to cadherin-11 counter-receptor inhibiting binding of cadherin-11 to its counter-receptor either in the context of a cell or in soluble form.

The invention discloses a novel effect and molecular mechanism of Paeonol and aims to provide an application of paeonol in preparing a medicament for preventing and treating a disease of TOPK activity abnormal elevation. Paeonol inhibits photodermatoses (sunburn and chronic actinic dermatosis) induced by ultraviolet rays (UV), which is realized by combining protein kinase (TOPK) originated from a T-LAK cell, inhibiting the activity thereof and blocking a TOPK signal channel. Immunopathology indicates that TOPK, P38 and JNK in skin lesion of photodermatoses are increased in expression. In a cell experiment, the activity of TOPK affects phosphorylation of P38 and JNK induced by UV. Through a molecular docking experiment, paeonol can be directly combined with TOPK to inhibit activation of TOPK and inhibit phosphorylation of p38, JNK and H2AX and secretion of inflammatory factors IL-6 and TNF-alpha. An animal experiment also verifies a cell experimental result.

The invention relates to a nucleic acid aptamer specifically binding to P-glycoprotein (P-gp), and a preparation method and application of the nucleic acid aptamer, and belongs to the technical fieldof biology. The nucleotide sequence of the nucleic acid aptamer is selected from SEQ ID No.1 to SEQ ID No.14 in sequence tables; the nucleic acid aptamer is prepared by screening, amplifying and sequencing an original random oligonucleotide library through an SELEX technology in combination with surface modified magnetic beads; the nucleic acid aptamer is small in molecular weight, can be chemically synthesized, and is low in cost; the affinity and the specificity are high; marking is facilitated; and the repeatability and the stability are high, and storage is easy. The nucleic acid aptamer can be made into a fluorescent molecular probe, and fluorescent visualization and quantification of P-gp on in-vitro tissues and cells of an organism are realized; and the nucleic acid aptamer can be specifically bound with P-gp, inhibits the function of P-gp, and becomes a potential nucleic acid type inhibitor of the function of P-gp.

The invention relates to a human Interleukin-2 (hIL-2) specific monoclonal antibody (mAb), or antigen binding fragment thereof, the binding of which to hIL-2 inhibits binding of hIL-2 to CD25 and the antibody is characterized by any of the parameters: the variable chain of the mAb comprises the amino acid sequence of SEQ ID NO 005 or SEQ ID NO 006; the binding to hIL-2 is characterized by a dissociation constant (K_D)≦7.5 nmol/L; the binding to hIL-2 is characterized by an off-rate (K_off)≦1×10⁻⁴ s⁻¹ and/or the antibody displays no measurable cross-reactivity to murine IL-2.

A composition for use in inhibiting the binding of a Norovirus to the histo-blood group antigen on the surface of epithelia is disclosed. The composition may contain a therapeutically effective amount of a binding-inhibiting compound and a carrier and/or excipient. The compounds may competitively bind a Norovirus that has the capability of binding with the histo-blood group antigens of secretor blood type, including A, B, AB, and O blood types. The compositions may be administered to a human prior to or after infection by a Norovirus, to prevent, ameliorate, or reduce the effects of an infection.

The present invention provides multispecific antibodies that bind to EGFR and CD28 (EGFRxCD28) as well as anti-EGFR antibodies. Such antibodies may be combined with a further therapeutic agent such as an anti-PD1 antibody. Methods for treating cancers (e.g., EGFR-expressing cancer) by administering the antibodies (e.g., and combinations thereof with anti-PD1) are also provided. The EGFRxCD28 antibodies of the present invention embody a tumor-targeted immunotherapeutic modality combined with PD-1 inhibition. These bispecific antibodies bind a tumor-specific antigen (TSA) (EGFR) with one arm and the co-stimulatory receptor, CD28, on T-cells with the other arm. Combination therapy with PD-1 inhibitors specifically potentiated intra-tumoral T cell activation, promoting an effector memory-like T cell phenotype without systemic cytokine secretion in a variety of syngeneic and human tumor xenograft models. Combining this class of CD28-co-stimulatory bispecific antibodies with the clinically validated anti-PD-1 treatment provides a well-tolerated antibody therapy with markedly enhanced anti-tumor efficacy.